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Aims

The left anterior descending (LAD) artery is the most frequently affected site by coronary artery disease. The prospective Lipid Rich Plaque (LRP) study, which enrolled patients undergoing imaging of non-culprits followed over
2 years, reported the successful identification of coronary segments at risk of future events based on near-infrared
spectroscopy-intravascular ultrasound (NIRS-IVUS) lipid signals. We aimed to characterize the plaque events
involving the LAD vs. non-LAD segments.

...................................................................................................................................................................................................
Methods
LRP enrolled 1563 patients from 2014 to 2016. All adjudicated plaque events defined by the composite of cardiac
and results
death, cardiac arrest, non-fatal myocardial infarction, acute coronary syndrome, revascularization by coronary by-

pass or percutaneous coronary intervention, and rehospitalization for angina with >20% stenosis progression and
reported as non-culprit lesion-related major adverse cardiac events (NC-MACE) were classified by NIRS-IVUS
maxLCBI4 mm (maximum 4-mm Lipid Core Burden Index) <_400 or >400 and association with high-risk-plaque characteristics, plaque burden >_70%, and minimum lumen area (MLA) <_4 mm2. Fifty-seven events were recorded with
more lipid-rich plaques in the LAD vs. left circumflex and right coronary artery; 12.5% vs. 10.4% vs. 11.3%,
P = 0.097. Unequivocally, a maxLCBI4 mm >400 in the LAD was more predictive of NC-MACE [hazard ratio (HR)
4.32, 95% confidence interval (CI) (1.93–9.69); P = 0.0004] vs. [HR 2.56, 95% CI (1.06–6.17); P = 0.0354] in nonLAD segments. MLA <_4 mm2 within the maxLCBI4 mm was significantly higher in the LAD (34.1% vs. 25.9% vs.
13.7%, P < 0.001).

...................................................................................................................................................................................................
Conclusion
Non-culprit lipid-rich segments in the LAD were more frequently associated with plaque-level events. LAD NIRSIVUS screening may help identify patients requiring intensive surveillance and medical treatment.
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Introduction
Coronary artery disease (CAD) plaques are more frequently seen in
the left anterior descending (LAD) artery and have a predilection for
the proximal segments.1–3 A ruptured plaque in the LAD resulting in
an acute anterior wall myocardial infarction (MI) is associated with
low left ventricular ejection fraction and a worse prognosis.4,5 The
Lipid Rich Plaque (LRP) study6 showed an association between highrisk plaque characteristics detected by intracoronary near-infrared
spectroscopy (NIRS)-intravascular ultrasound (IVUS)—including a
NIRS-derived maxLCBI4 mm >400 and an IVUS plaque burden (PB)
>_70% or minimum lumen area (MLA) <_4 mm2—and subsequent
coronary events. However, there has been no natural history study
exploring the hypothesis of whether lipid-rich plaques, as assessed by
NIRS-IVUS, located in the LAD are associated with more future
events as compared to other vessels, which is the objective of the
current analysis from the LRP study.

Methods
The design of the LRP study has been reported elsewhere.7 Briefly, the
LRP study was an international, multicentre, prospective cohort study
conducted in patients with suspected CAD who underwent cardiac catheterization with possible ad hoc percutaneous coronary intervention
(PCI) for an index event. Following successful PCI, additional NIRS-IVUS
imaging data were obtained in at least 50 mm of the non-stented segment
from two or more major coronary arteries. Plaque-level events were collected in the subsequent 2 years. Ethics committees at the enrolling
centres approved the study protocol, and all participants provided written informed consent.

..
.. Coronary angiography analysis and NIRS..
.. IVUS imaging protocol and analysis
.. All quantitative coronary angiographic analysis was done via offline soft..
.. ware, CAAS Workstation 7.3 (Pie Medical Imaging BV, Maastricht, The
.. Netherlands) by an independent core laboratory [Angiographic and
.. Invasive Imaging Core Lab, MedStar Cardiovascular Research Network
..
.. (MCRN), Washington, DC, USA].
..
NIRS-IVUS was performed using a 3.2-Fr imaging probe with a 40..
.. MHz ultrasound transducer, rotated at 960 rpm (16 fps) to acquire 160
.. NIRS spectra per second with a pullback speed of 0.5 mm/s (Infraredx, a
..
.. Nipro Company, Bedford, MA, USA). All the site-blinded non-culprit
.. scans were un-blinded by the core lab and assessed using validated NIRS.. IVUS offline analysis software—QIVUS (version 3.0.16.0, Medis Medical
..
.. Imaging Systems, The Netherlands). All NIRS information was displayed
.. on an automatically generated signal map known as the ‘chemogram’,
..
.. which indicated the location of lipid-rich plaque within the vessel wall. A
.. quantitative image metric is automatically reported as a numerical Lipid
..
.. Core Burden Index (LCBI), which represents the fraction of the chemo.. gram yellow pixels that are yellow times 1000.
..
Each coronary artery with available NIRS-IVUS imaging was divided
..
.. into 30-mm segments (also referred to as ‘Ware’ segments) beginning
.. from the ostium of the vessel. The proximal segment was defined by the
..
.. first 30 mm of the NIRS chemogram obtained in the vessel, the mid.. segment as the next 30 mm, and the distal segment as the remaining che..
.. mogram <_30 mm in length. If the total length of the imaged vessel
.. exceeded 90 mm, the segment beyond 90 mm was defined as the ‘far dis..
.. tal’ segment. Additionally, each 30-mm coronary ‘Ware’ segment was fur.. ther sub-divided into 10-mm subsegments. Once this segmentation was
..
.. completed, the software automatically computed the maximum 2- and 4.. mm LCBI within each ‘Ware’ segment. LCBI is a quantitative summary
.. metric of lipid within a scanned or selected region. The maxLCBI was
4 mm
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Study endpoints and definitions
An independent Clinical Events Committee at the Cleveland Clinic
Coordinating Center for Clinical Research (C5R, Cleveland, OH, USA)
that was blinded to the NIRS-IVUS findings adjudicated the primary outcome events, defined as the composite of non-fatal MI, acute coronary
syndrome (ACS), revascularization by coronary artery bypass grafting
(CABG) or PCI, and rehospitalization for angina with >20% stenosis progression. Together these events were reported as non-culprit lesionrelated major adverse cardiac events (NC-MACE).

Statistical analysis
Prespecified subgroups of segments were defined according to LAD (vs.
non-LAD) with maxLCBI4 mm <_400 vs. >400. For categorical variables,
frequencies and proportions were used to summarize categorical data.
For tabular summaries of proportions, the denominator was the number
of subjects with non-missing data. v2 or Fisher’s exact tests and ANOVA
F-tests were used to test the equality of baseline plaque characteristics
across four groups (LAD with maxLCBI4 mm <_400; LAD with
maxLCBI4 mm >400; non-LAD with maxLCBI4 mm <_400; non-LAD with
maxLCBI4 mm >400). NC-MACE rates were depicted using the Kaplan–
Meier (KM) method and compared using the likelihood-ratio test, which
accounts for the clustering of plaques within patients. For the plaquelevel association of NC-MACE with maxLCBI4 mm <_400 vs. >400 in LAD
and non-LAD locations, a random-effect Cox regression model, with a
random effect for patients, was used, with maxLCBI4 mm, LAD vessel indicator, and interaction between them while adjusting for PB within
maxLCBI4 mm (>_70% vs. <70%) and MLA within maxLCBI4 mm (<_4 mm2
vs. >4 mm2). The proportionality of the hazards assumption was tested
for each predictor in the model using the Kolmogorov-type Supremum
test for proportional hazards assumption. No significant evidence was
found that the proportionality assumption does not hold. All analyses
were performed using SAS software, version 9.4 (SAS Institute, Cary,
NC, USA). The data underlying this article will be shared on reasonable
request to the corresponding author.

Results
From February 2014 through March 2016, a total of 1563 patients
were enrolled in the main LRP study. After excluding patients without analysable NIRS (n = 11), 281 patients with maxLCBI4 mm <250
(who per study design were randomly excluded from the follow-up)
and evaluable age at the time of catheterization, a total of 1269
patients (and 5749 Ware segments) were followed through
24 months. In the overall population (irrespective of follow-up allocation), lipid-rich plaques (maxLCBI4 mm > 400) were present in 11.5%
of the imaged plaques, of which 1% had a PB >_70% and 27% had an
MLA <_4 mm2 (Supplementary data online, Table S1).
As shown in Table 1, mean patient age and the percentage of male
participants were similar across all four groups: (i) non-LAD and
maxLCBI4 mm >400, (ii) LAD and maxLCBI4 mm >400, (iii) non-LAD
and maxLCBI4 mm <_400, and (iv) LAD and maxLCBI4 mm <_400. Of
note, the percentage of patients with diabetes mellitus was higher in
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the two groups with maxLCBI4 mm >400. Numerically, we observed
more lipid-rich plaques in the LAD than in the left circumflex (LCX)
and right coronary artery (RCA): 12.5% vs. 10.4% and 11.3%, respectively, P = 0.097. The number of plaques with PB >_70% within the
maxLCBI4 mm in the RCA was 1.6%, followed by the LAD (1.1%) and
LCX (0.6%). An MLA <_4 mm2 within the maxLCBI4 mm was observed
more in the LAD and LCX than in the RCA: 34.1% vs. 25.9% vs.
13.7%, respectively, P < 0.001 (Supplementary data online, Table S1).
There were 57 plaque-level events through the 2-year follow-up
period. Lipid-rich plaque (maxLCBI4 mm > 400) was present in 20/57
(35.1%), a large PB (>_70%) was present in 6/57 (10.5%), and a small
MLA (<_4 mm2) was present in 26/57 (45.6%). Combining these plaque characteristics, 11/57 (19.3%) of the events were in segments
with lipid-rich plaques and a small MLA (defined as <4.0 mm2); 5/57
(8.8%) were in segments with lipid-rich plaques and a large PB
(>_70%), and 4 (7%) had all three high-risk plaque characteristics.
Figure 1 shows the major events and their locations. There were
44 PCIs and 13 CABGs. The mean maxLCBI4 mm of the Ware segments treated with PCI was 301.9 ± 195.6 and with CABG was
376.4 ± 240.4. The second most common event type was ACS
(n = 18), which had a mean maxLCBI4 mm of 328.1 ± 224.5. The Ware
segments associated with eight non-fatal MI had a maxLCBI4 mm of
393.1 ± 264.6, the largest observed among the plaque events.
Patients who underwent CABG events had the largest average PB
(58.68%) and smallest average MLA (5.37 mm2); non-fatal MI, conversely, occurred in those plaques with the largest average LCBI
(Figure 1).
More than half of the plaque events occurred in the LAD, followed
by the LCX and RCA (Table 2). Revascularizations were the most
common plaque events, and nearly half were performed in the LAD.
All non-fatal MIs but one were located in the LAD (in the proximal
or midsegments) (Figure 1). As shown in Figure 2, in each of the three
vessels (LAD, LCX, and RCA), events were more commonly associated with lesions with a maxLCBI4 mm >400 or a PB >_70%, although
the number of events and differences was greater in the LAD than in
the LCX or RCA. A maxLCBI4 mm >400 was predictive of NCMACE both for LAD location [hazard ratio (HR) 4.32, 95% confidence interval (CI) (1.93–9.69); P = 0.0004] and for non-LAD location [HR 2.56, 95% CI (1.06–6.17); P = 0.0354]. In Supplementary
data online, Figure S1, the KM curves by vessel location according to
the MLA <_4 mm2 are given. Case examples of patients with high-risk
plaques are shown in Figures 3 and 4.

Discussion
The main findings of this report are as follows: (i) plaque-level events
were commonly found in acknowledged culprit sites such as LAD
and proximal locations; the plaque-level events were more frequently observed in untreated lipid-rich plaques. (ii) Revascularizations
were the most common plaque events, and nearly half were performed in the LAD. All non-fatal MIs but one were located in the
LAD.
In a pooled analysis of 5250 patients, thrombotic lesions, as
detected by coronary angiography, were present more frequently in
the LAD and RCA in their proximal segments.1 It has been proposed
that the local shear stress conditions favour the accumulation of lipid
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defined as the maximum LCBI of the 4-mm region within the greatest
lipid burden.
The greyscale IVUS frames corresponding to the maxLCBI4 mm segment were analysed. Vessel and lumen areas were drawn at 1-mm intervals. The difference between the vessel and lumen areas was the plaque
area, and PB was the ratio of the plaque to the vessel area.
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Table 1

Baseline characteristics

Characteristic

Overall
(N 5 1269)

Non-LAD and
maxLCBI4 mm
>400 (N 5 245)

LAD and
maxLCBI4 mm
400 (N 5 391)

LAD and
maxLCBI4 mm
>400 (N 5 253)

P-value

0.572

....................................................................................................................................................................................................................
Age (years), mean ± SD

64 ± 10

65 ± 10

64 ± 11

64 ± 10

63 ± 11

Male, n (%)

882 (69.5)

279 (73.4)

158 (64.5)

273 (69.8)

172 (68)

Diabetes mellitus, n (%)
Diabetes requiring

464 (36.7)
162 (13.1)

115 (30.3)
33 (8.8)

108 (44.3)
48 (19.9)

133 (34)
43 (11.3)

108 (43.4)
38 (15.6)

<0.001
<0.001

685 (54.9)
282 (22.6)

197 (52.4)
80 (21.3)

118 (49.6)
54 (22.7)

220 (57.1)
84 (21.8)

150 (60.5)
64 (25.8)

0.056
0.579

1018 (80.5)

306 (80.7)

199 (81.6)

311 (79.7)

202 (80.2)

0.951

636 (56.1)
294 (23.5)

180 (53.7)
94 (25.1)

125 (58.1)
59 (24.6)

204 (57.1)
85 (21.9)

127 (56.2)
56 (22.5)

0.733
0.705

Prior PCI, n (%)

567 (44.8)

185 (48.7)

114 (47.1)

160 (40.9)

108 (42.9)

0.133

Presentation with ACS, n (%)
Chronic renal

214 (16.9)
101 (8)

51 (13.4)
27 (7.1)

43 (17.6)
27 (11.1)

66 (16.9)
26 (6.7)

54 (21.3)
21 (8.3)

0.075
0.204

Hyperlipidaemia, n (%)
PCI during index, n (%)

1011 (80.3)
1110 (87.5)

307 (81.6)
347 (91.6)

185 (76.4)
210 (85.7)

314 (80.5)
336 (85.9)

205 (81.7)
217 (85.8)

0.389
0.046

>_50 mm of eligible

1135 (89.4)

340 (89.5)

222 (90.6)

335 (85.7)

238 (94.1)

0.008

97.893 ± 43.379

91.646 ± 40.813

107.192 ± 44.211

88.924 ± 40.565

112.132 ± 45.308

<0.001

MaxLCBI4 mm, mean ± SD
Avg LCBI4 mm,a mean ± SD

359.638 ± 174.884
220.577 ± 135.204

254.524 ± 111.531
149.365 ± 87.701

535.539 ± 103.798
327.623 ± 131.745

254.606 ± 107.756
162.869 ± 89.522

509.498 ± 142.746
313.059 ± 136.611

<0.001
<0.001

Ware segment per patient,

4.533 ± 1.735

4.355 ± 1.69

4.914 ± 1.808

4.148 ± 1.639

5.024 ± 1.695

<0.001

0.114

insulin, n (%)
History of smoking, n (%)
Current smoker, n (%)
Hypertension, n (%)
Family history of CAD, n (%)
Prior MI, n (%)

insufficiency, n (%)

vessel, n (%)
Imaged vessel length (mm),
mean ± SD

mean ± SD
ACS, acute coronary syndrome; CAD, coronary artery disease; LAD, left anterior descending; LCBI, lipid core burden index; MI, myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation.
a
Average maxLCBI4 mm across all Ware segments per patient.

Figure 1 Number of events in each of the coronary vessel locations. The number in brackets is the number of plaque-level events. ACS, acute coronary syndrome (in green); CABG, coronary artery bypass graft (in yellow); LAD, left anterior descending; LCBI, Lipid Core Burden Index (the number represents the mean of maxLCBI4 mm); LCX, left circumflex; MI, myocardial infarction (in dark red); MLA, minimum lumen area; OM, obtuse
marginal; PB, plaque burden; PCI, percutaneous coronary intervention (in orange); ProgrAng, progressive angina (in brown); Prox, proximal; RCA,
right coronary artery. *Ware segment may be associated with multiple event types.
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Table 2

Distribution of 57 plaque-level events by clinical event type and their angiographic location

Vessel

Any event

PCIa

CABG

ACS

LAD
LCX

29/57 (50.9%)
18/57 (31.6%)

21/43 (48.8%)
15/43 (34.9%)

8/13 (61.5%)
2/13 (15.4%)

RCA

10/57 (17.5%)

7/43 (16.3%)

3/13 (23.1%)

Non-fatal MI

Progressive angina

13/18 (72.2%)
2/18 (11.1%)

7/8 (87.5%)
1/8 (12.5%)

1/5 (20%)
1/5 (20%)

3/18 (16.7%)

0/8 (0.0%)

3/5 (60%)

....................................................................................................................................................................................................................

Figure 2 (Top row, A-C)Kaplan–Meier curves for patients with maxLCBI4 mm >400 or not in the (A) LAD, (B) LCX, and (C) RCA ; (Bottom row,
A-C ) Kaplan-Meier curves for patients with plaque burden >_70% or not in the (A) LAD, (B) LCX, and (C) RCA. LAD, left anterior descending; LCBI,
Lipid Core Burden Index; LCX, left circumflex; MACE, major adverse cardiac events; PB, plaque burden; RCA, right coronary artery.

within the vessel wall in these areas.8 Particularly in the proximal segment of the LAD, the plaque is mostly located opposite to the takeoff
of the LCX, sparing the carina, which makes them eccentric plaques
in this location. IVUS imaging studies have also confirmed the same
pattern of distribution of these lipid-rich and large PB plaques.9,10 For
example, in the PROSPECT ABSORB study,11 which included
patients with large PB detected by IVUS, most treated lesions were
located in the two most proximal segments in the coronary vessel,
and approximately one-third were located in each of the three major
coronary vessels. In the LRP study, by protocol, all obstructive lesions
were treated at the index procedure; 47% of the PCIs at baseline
were in the LAD, 26% in the LCX, and 25% in the RCA. Even though
most of the index PCIs took place in the LAD, revascularizations during follow-up were also performed most frequently in the LAD.
There have been some natural history studies using non-invasive
imaging such as computed tomography angiography (CTA) exploring
whether the vessel location is associated with major coronary events.

..
.. In a CTA study involving 1127 patients, Min et al.12 found that the
.. proximal LAD and number of diseased vessels were predictors of all..
.. cause mortality at 1 year. Similarly, Pundziute et al.13 reported that
.. patients with coronary lesions in the LAD had a greater risk of coron..
.. ary events (i.e., cardiac death, non-fatal MI, unstable angina requiring
.. hospitalization, and revascularization) in both univariate and multi..
.. variate analyses. In line with LRP study observations, the plaque char..
.. acteristics observed in CTA studies that conferred high risk to future
.. cardiac events included the presence of low-attenuation plaques (i.e.,
..
.. lipid-rich plaque) and the degree of obstruction. Nakanishi et al.14
.. reported that the number of low-attenuation plaques in the LAD
..
.. was an independent predictor of ACS.
..
..
.. Limitations
.. Despite being the largest-ever natural history study using IVUS imag..
.. ing, the number of plaque-level events in the LRP study was relatively
.. small. Second, this study was carried out as a post hoc analysis from
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Plaque events may be associated with multiple event types.
ACS, acute coronary syndrome; CABG, coronary artery bypass graft; LAD, left anterior descending; LCX, left circumflex; MI, myocardial infarction; OM, obtuse marginal; PCI,
percutaneous coronary intervention; RCA, right coronary artery.
a
Single OM1 not included in PCI count in comparison with Figure 1.
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man with a past medical history of hyperlipidaemia, type 1 diabetes mellitus, and hypothyroidism, and he is a former smoker. Index cardiac catheterization with index angiography in 2014 showed stenosis of the left main and LAD arteries (A). About a year later, the patient presented to the emergency room complaining of ‘chest discomfort’ and pressure on exertion with difficulty in taking a deep breath and intermittent shortness of breath.
Labs revealed biomarker elevation. The patient was diagnosed with non-fatal myocardial infarction and subsequently underwent catheterization and
percutaneous coronary intervention with a drug-eluting stent to the mid-LAD during this hospitalization (B—note the yellow lines demarcating the
maxLCBI4 mm). (C) The chemogram of the ‘Ware’ segment (showing the maxLCBI4 mm demarcated by the two orange lines corresponding to the
broken orange lines on the angiogram) shows a diffuse segment of lipid-rich plaque on the near-infrared spectroscopy chemogram map at index. (D)
The corresponding intravascular ultrasound cross-sections with the chemogram rings. Note the presence of calcium in two quadrants.

the parent study and was not powered for vessel-level comparison of
the relationship between the maxLCBI4 mm and non-culprit events.
Further studies will be required to evaluate the correlation of NIRSIVUS maxLCBI4 mm >400 with other plaque-event predictors on an
epicardial vessel level.

Conclusions
In the LRP study, plaque-level events were commonly found in the
LAD location, especially in untreated lipid-rich plaques within the first

..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.

2 years. Non-culprit segments in the LAD with maxLCBI4 mm values
>400 were more frequently associated with plaque-level events than
the lipid-rich segments in the other epicardial vessels. Because most
events occurred in the LAD, screening of this vessel with NIRS-IVUS
may help identify patients requiring intensive medical treatment and
closer follow-up.

Supplementary data
Supplementary data are available at European Heart Journal - Cardiovascular
Imaging online.
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Figure 3 Case example of a patient with a lipid-rich and large plaque in the left anterior descending (LAD) artery. The patient is an 83-year-old
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Figure 4 Case example of a patient with the three high-risk plaque characteristics. This patient is a 60-year-old woman with a positive smoking history and a past medical history of hyperlipidaemia, hypertension, insulin-dependent diabetes mellitus, congestive heart failure, peripheral vascular disease, and cerebrovascular accident. (A) Index angiography of the imaged vessel (i.e., right coronary artery [RCA). At baseline, the patient had
percutaneous coronary intervention of the proximal RCA. (B) After 308 days, the patient was re-hospitalized due to retrosternal dull aching chest
pain, and angiography was done. On angiography, a new diffuse lesion was observed in the proximal RCA, and the patient was treated with stent implantation. The two yellow lines limit the location of the maxLCBI4 mm. (C) The chemogram of the ‘Ware’ segment shows a diffuse multifocal lipid-rich
plaque at the maxLCBI4 mm (orange lines). (D) Representative frames from the max LCBI4 mm region. Note the presence of calcium in two quadrants.
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